Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme.

When the authors compared treated patients with historical controls as in our study, they showed a trend towards a treatment benefit on time to reach EDSS 6.0 (relative risk 0.77, CI 0.58 to 1.02), which is comparable with our results considering they had a much smaller treated cohort (n=868 vs 4986) with shorter follow-up time (mean 5.2 and median 5.1 years vs 8.7 and 10 in our study).

also in 53,322 other papers